Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease.

  • sponsor
    Neurim Pharmaceuticals LTD.
Updated on 8 December 2020


Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease.


This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

All study-related exams, tests, procedures and medication will be provided free of charge. Reasonable compensation for time and travel may be provided.

Clinical Study IdentifierTX145468
SponsorNeurim Pharmaceuticals LTD.
Last Modified on8 December 2020


Yes No Not Sure

Inclusion Criteria

Patient and caregiver are willing to take part in the entire study
Signed informed consent from the patient and the caregiver
Patient has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months
Patient has mild probable AD as consistent with criteria established by the NIA-AA
CT/MRI scan with finding consisted with probable AD obtained during the last 12 months before Screening
Patient has an MMSE score of 21-26 (inclusive) at Screening
Patient has a Clinical Dementia Rating Global Score (CDR-GS) of 0.5-1 (mild dementia) at Screening
Patients receiving prescribed drugs for treatment of AD including acetyl cholinesterase inhibitors [eg, donepezil, galantamine, rivastigmine] should be on a stable dose for at least 3 months before Screening
Patient has a negative drug screen (benzodiazepines or opiates) at Screening
Female patients must have had last natural menstruation ≥ 24 months before Screening, OR be surgically sterile
Male patients must agree to use of effective contraception if female partner is of childbearing potential, OR be surgically sterile

Exclusion Criteria

Patient has an alternative cause for dementia other than AD as determined by CT or MRI scan
Patient has evidence of any clinically significant neurodegenerative disease
Patient has been diagnosed with the following Axis I disorders (DSM V criteria)
Patient has a history of uncontrolled or untreated cardiovascular, endocrine, gastrointestinal, respiratory, or rheumatologic disorders within the past 5 years
Patient has severe pain that is likely to interfere with sleep
Continuous use of benzodiazepines or other sedative-hypnotics during the 2 weeks before Screening
Use of any kind of melatonin/melatonin agonist during the 2 weeks before Screening
Patient has known or suspected hypersensitivity to exogenous melatonin or melatonin receptor agonists
Patients with an irregular lifestyle or life pattern (eg, shift workers, patients likely to be jet lagged)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note